R-G-Cysteic Acid Peptides for Ocular Adhesion Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for disorders such as inflammation, wound-healing, thrombosis, cancer metastasis, and retinal diseases lack effective methods to inhibit cellular adhesion to RGD binding sites, which are crucial for managing conditions like macular degeneration and vitreoretinal detachment.
Innovation Solution
Development of novel compounds like R-G-Cysteic Acid peptides and their derivatives, which inhibit cellular adhesion to RGD binding sites by forming stronger hydrogen bonds with integrin binding sites, facilitating therapeutic interventions and diagnostic imaging.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional RGD peptides are used to inhibit cellular adhesion, then therapeutic effects are achieved, but binding affinity and effectiveness are limited due to weaker hydrogen bonding
Solution Approach 1:
The patent modifies the chemical structure of conventional RGD peptides by replacing the aspartic acid residue with cysteic acid, which contains a sulfonic acid group. This parameter change in the chemical composition enables the formation of stronger hydrogen bonds with integrin binding sites, thereby improving cellular adhesion inhibition effectiveness while maintaining peptide functionality.
Solution Approach 2:
The invention creates a composite peptide structure that combines the RGD motif with cysteic acid residues, forming a hybrid molecule that integrates the cell-adhesion-blocking RGD sequence with the enhanced hydrogen-bonding capability of sulfonic acid groups. This composite structure achieves both therapeutic effectiveness and strong molecular binding.
2Reliability
If stronger binding affinity is achieved through modified peptides, then therapeutic effectiveness improves, but complexity of peptide synthesis and formulation increases
Solution Approach 1:
The patent employs segmental protection strategies in peptide synthesis, where specific residues (particularly cysteic acid and arginine) are selectively protected and deprotected at different stages. This segmentation of the synthesis process into controlled stages simplifies the overall manufacturing complexity while enabling the formation of the desired strong-binding peptide structure.
Solution Approach 2:
The patent uses protecting groups as intermediary molecules during synthesis that temporarily mask reactive functional groups. These intermediaries facilitate controlled peptide bond formation and prevent unwanted side reactions, thereby simplifying the synthesis process while maintaining the integrity of the strong-binding peptide structure.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These peptides effectively inhibit cellular adhesion, promoting posterior vitreous detachment, reducing scar formation, and targeting cancer cells, while also serving as diagnostic and therapeutic agents for various pathological conditions.
Implementation Method 1
forming stronger hydrogen bonds with integrin binding sites
Data Source
AI summary
Compounds comprising R-G-Cysteic Acid (i.e., R-G-NH—CH(CH2—SO3H)COOH or Arg-Gly-NH—CH(CH2—SO3H)COOH) and derivatives thereof, including pharmaceutically acceptable salts, hydrates, stereoisomers, multimers, cyclic forms, linear forms, drug-conjugates, pro-drugs and their derivatives. Also disclosed are methods for making and using such compounds including methods for inhibiting cellular adhesion to RGD binding sites or delivering other diagnostic or therapeutic agents to RGD binding sites in human or animal subjects.